Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
出版年份 2020 全文链接
标题
Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
作者
关键词
-
出版物
OncoTargets and Therapy
Volume Volume 13, Issue -, Pages 12367-12382
出版商
Informa UK Limited
发表日期
2020-12-01
DOI
10.2147/ott.s287944
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
- (2020) Ayalew Tefferi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
- (2020) Heinz Gisslinger et al. Lancet Haematology
- Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
- (2020) Elisabeth Oppliger Leibundgut et al. HAEMATOLOGICA
- Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
- (2020) Onima Chowdhury et al. LEUKEMIA
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
- (2020) Giacomo Coltro et al. Blood Advances
- Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
- (2019) Nico Gagelmann et al. BLOOD
- Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants
- (2019) Christian Pecquet et al. BLOOD
- Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface
- (2019) Nami Masubuchi et al. LEUKEMIA
- Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms
- (2019) Paola Guglielmelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Novel Drivers and Modifiers of MPL-dependent Oncogenic Transformation Identified by Deep Mutational Scanning
- (2019) Jessica L Bridgford et al. BLOOD
- JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2 V617F mutated disease
- (2018) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The co-occurrence of driver mutations in chronic myeloproliferative neoplasms
- (2018) Prajwal Boddu et al. ANNALS OF HEMATOLOGY
- PPM1D truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells
- (2018) Josephine D. Kahn et al. BLOOD
- MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
- (2018) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
- (2018) Paola Guglielmelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
- (2018) Maura Nicolosi et al. LEUKEMIA
- Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
- (2018) Ayalew Tefferi et al. LEUKEMIA
- U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
- (2018) Ayalew Tefferi et al. LEUKEMIA
- GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
- (2018) Tiziano Barbui et al. LEUKEMIA
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients
- (2018) Andrew T. Kuykendall et al. AMERICAN JOURNAL OF HEMATOLOGY
- JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
- (2018) Julia Czech et al. LEUKEMIA
- Classification and Personalized Prognosis in Myeloproliferative Neoplasms
- (2018) Jacob Grinfeld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
- (2018) Annalisa Pacilli et al. Blood Cancer Journal
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders
- (2017) N Maslah et al. LEUKEMIA
- Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
- (2017) A Tefferi et al. LEUKEMIA
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
- (2017) F Passamonti et al. LEUKEMIA
- Genetic Risk Assessment in Myeloproliferative Neoplasms
- (2017) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
- (2017) Lucia Masarova et al. Lancet Haematology
- Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms
- (2016) Giuseppe Gaetano Loscocco et al. AMERICAN JOURNAL OF HEMATOLOGY
- Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients
- (2016) Mahnur Haider et al. AMERICAN JOURNAL OF HEMATOLOGY
- LNK mutations in familial myeloproliferative neoplasms
- (2016) Elisa Rumi et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
- (2016) A. Alvarez-Larran et al. HAEMATOLOGICA
- Loss ofEzh2synergizes withJAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
- (2016) Takafumi Shimizu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Thrombopoietin receptor is required for the oncogenic function of CALR mutants
- (2016) H Nivarthi et al. LEUKEMIA
- Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin
- (2016) T Balligand et al. LEUKEMIA
- JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
- (2016) G Barosi et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
- (2016) Lasse Kjær et al. PLoS One
- Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
- (2016) S. Elf et al. Cancer Discovery
- Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
- (2016) A. Alvarez-Larran et al. HAEMATOLOGICA
- Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
- (2015) Nicole C.C. Them et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical and molecular response to interferon- therapy in essential thrombocythemia patients with CALR mutations
- (2015) E. Verger et al. BLOOD
- Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
- (2015) J. D. Milosevic Feenstra et al. BLOOD
- Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
- (2015) I. Chachoua et al. BLOOD
- Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
- (2015) X. Cabagnols et al. BLOOD
- Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera
- (2015) H. Gisslinger et al. BLOOD
- DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
- (2015) J. Nangalia et al. HAEMATOLOGICA
- Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
- (2015) D Pietra et al. LEUKEMIA
- Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms
- (2015) J-P Defour et al. LEUKEMIA
- Co-existence ofJAK2V617F andCALRmutations in primary myelofibrosis
- (2015) Lurdes Zamora et al. LEUKEMIA & LYMPHOMA
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Mutation Order on Myeloproliferative Neoplasms
- (2015) Christina A. Ortmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
- (2015) Gabriela M. Baerlocher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
- (2015) P Guglielmelli et al. Blood Cancer Journal
- Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
- (2015) S Cerquozzi et al. Blood Cancer Journal
- Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
- (2015) T Barbui et al. Blood Cancer Journal
- DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
- (2015) J. Nangalia et al. HAEMATOLOGICA
- Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
- (2014) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm
- (2014) V. Sangkhae et al. BLOOD
- The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
- (2014) A. Tefferi et al. BLOOD
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution
- (2014) X Cabagnols et al. LEUKEMIA
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
- (2014) P Guglielmelli et al. LEUKEMIA
- Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
- (2013) G. Rotunno et al. BLOOD
- JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
- (2013) E. Rumi et al. BLOOD
- Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon -2a
- (2013) A. Quintas-Cardama et al. BLOOD
- Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
- (2013) Odile Moulard et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse
- (2013) T. Lange et al. HAEMATOLOGICA
- MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
- (2013) Jonas S. Jutzi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
- (2012) S.-J. Zhang et al. BLOOD
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
- (2012) T. Barbui et al. BLOOD
- SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
- (2012) T. L. Lasho et al. BLOOD
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- The JAK2 exon 12 mutations: A comprehensive review
- (2011) Linda M. Scott AMERICAN JOURNAL OF HEMATOLOGY
- EZH2 mutational status predicts poor survival in myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
- (2011) F. Passamonti et al. BLOOD
- Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
- (2010) H. Alchalby et al. BLOOD
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
- (2010) A Tefferi et al. LEUKEMIA
- Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
- (2010) D Caramazza et al. LEUKEMIA
- Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2 V617F clones without affecting TET2 mutant cells
- (2010) J-J Kiladjian et al. LEUKEMIA
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Advances in Understanding and Management of Myeloproliferative Neoplasms
- (2009) A. M. Vannucchi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Calreticulin: non-endoplasmic reticulum functions in physiology and disease
- (2009) Leslie I. Gold et al. FASEB JOURNAL
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
- (2009) Masashi Sanada et al. NATURE
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Targeting Ras in Myeloid Leukemias
- (2008) B. S. Braun et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started